Open-Label, Bridging Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Treatment- Naive and Treatment-Experienced Russian Subjects With Genotype 1 Chronic Hepatitis C.

Trial Profile

Open-Label, Bridging Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Treatment- Naive and Treatment-Experienced Russian Subjects With Genotype 1 Chronic Hepatitis C.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2015

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Dec 2012 Actual initiation date changed from Dec 2011 to Jan 2012 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Company (Janssen-Cilag) added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top